Navigation Links
Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium
Date:11/9/2007

ed thus far in the discovery of drugs that will inhibit this pathway without causing excessive toxicity.

To date, over 1,500 patients have been treated with perifosine in trials conducted both in the US and Europe. Its safety profile is distinctly different from that of most cytotoxic agents. It does not cause myelosuppression (depression of the immune system) or alopecia (hair loss) like many currently available treatments for cancer. In phase 1/2 trials it has induced tumor regressions and/or caused disease stabilization in a variety of tumor types. Responding patients, including stable disease, have been treated for months to almost 3 years, on both the daily and weekly schedule.

KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris, Inc. (Nasdaq: AEZS; TSX: AEZ) in the United States, Canada and Mexico.

About Renal Cell Carcinoma

In 2007, an estimated 51,000 new cases of RCC and 13,000 deaths attributable to RCC are expected in the US. The National Cancer Institute reports a rising incidence of RCC at a rate of approximately 2% per decade. The disease occurs predominantly in the seventh and eighth decades in life, and it affects nearly twice as many men as women.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide oral gelcap), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabete
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...., Dec. 1 Vanda Pharmace... in The Lancet , one of the world,s leading medic...el circadian regulator, experimental compound tasi...et al(1) is entitled "Melatonin agonist tasimelteo...e shift: two randomised controlled multicentre tri...
(Date:12/1/2008)...y shows the Prox1 gene is a two-way switch that, i...o be reprogrammed so that they lose their identity... , MEMPHIS, Tenn., Dec. 1 /PRNewswire-USNewswi... Hospital have discovered that a certain different... that it requires the constant expression of a gen...
(Date:12/1/2008)... 1 GeoVax Labs, Inc.,(O...nology company developing,human vaccines for dise...) and,other infectious agents, announced today th...s will take place in twelve sites across North and...laboration with The National Institutes of,Health...
(Date:11/28/2008)... Nov. 28 Eli Lilly and C...tal New Drug Application (sNDA) from,the U.S. Foo...uloxetine HCl),for the management of chronic pain...first half of 2009, adding data from a recently co...pain of the knee. , The decision does not a...
Breaking Medicine Technology:Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Autism Learning Disabilities and ADHD Experts Convene at the Help Group Summit 26681 1Autism Learning Disabilities and ADHD Experts Convene at the Help Group Summit 26681 2Autism Learning Disabilities and ADHD Experts Convene at the Help Group Summit 26681 3New York City Skin Care Leader Juva Offering Latest Skin Resurfacing Innovation 26676 1New York City Skin Care Leader Juva Offering Latest Skin Resurfacing Innovation 26676 2Neurotechnology Releases SentiSight 2 0 SDK Universal Object Recognition Technology 5040 1Neurotechnology Releases SentiSight 2 0 SDK Universal Object Recognition Technology 5040 2Neurotechnology Releases SentiSight 2 0 SDK Universal Object Recognition Technology 5040 3UTSA UTHSCSA publish results on bio threat agent 7885 1UTSA UTHSCSA publish results on bio threat agent 7885 2
...Cancer and Other Human,Papillomavirus Related Dise...e Phase III Clinical Studies Which Included More T...e publishes the most comprehensive,and robust clin...YON, France, 10th May2007 – New clinical stu... of Gardasil® in the,prevention of cervical ca...
...007 - Antisense,Pharma, a German biopharmaceutical...ignant tumors, today announced, that data from the...a will be,presented at the 43rd Annual Meeting of ...which will be held in Chicago, Illinois,U.S.A, fr... dose-finding Phase,IIb-trial adult patients with ...
Other Medicine Technology:Gardasil Demonstrates Up to 100% Efficacy 2Gardasil Demonstrates Up to 100% Efficacy 3Gardasil Demonstrates Up to 100% Efficacy 4Gardasil Demonstrates Up to 100% Efficacy 5Gardasil Demonstrates Up to 100% Efficacy 6Gardasil Demonstrates Up to 100% Efficacy 72007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with,AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion 22007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with,AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion 3
(Date:12/1/2008)... Dec. 1 ETHICON, Inc., a Johnson ... completed the divestiture of its Professional Wou...l terms of the transaction are not being disclosed...ne Equity Partners has acquired the Professional W...dvanced wound care brands as PROMOGRAN Matrix Woun...
(Date:12/1/2008)...1 Democratic National C...lowing statement commemorating World AIDS Day on i....newscom.com/cgi-bin/prnh/20080519/DNCLOGO ) , ...DS Day, and while we have made strides, much work ...th a national and global strategy. We must focus ...
(Date:12/1/2008)...., Dec. 1 MassMutual Retirement Se...upport its increasing nonprofit business. Nonprofi...to last year. , , Dan Darby joined MassMut...or the Western region. He reports to M. Palmer Whi..., for MassMutual,s Retirement Services Division, w...
(Date:12/1/2008)..., supplements can also trigger acute organ failure...ay News) -- Antibiotics are the single largest cla...liver injury (DILI), researchers say. , The con...cute liver failure in the United States and is the...re. , DILI is caused by a wide range of prescri...
Breaking Medicine News(10 mins):Health News:ETHICON Completes Divestiture of Professional Wound Care Business to One Equity Partners 2Health News:ETHICON Completes Divestiture of Professional Wound Care Business to One Equity Partners 3Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 2Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 3Health News:Antibiotics Largest Cause of Drug-Induced Liver Damage 2
...study researchers say health professionals and pat...ectively manage the risks associated with over the... headache is one of the most common condition that...ng Over-the-Counter Medications. Some of the other...
...y started with a big bang, bringing hope and aspir...e and nature had ideas of their own. 2001 opened...and man made ones. The first internationally rep... 1st in California when a jet bound for S.F plugge...
...ave now identified a group of genes known as a gen...st cancer patients may be at high risk for having ...gene expressions in 286 tumor samples from 209 lym...were examined. The patients had not received hormo...
...n cause skin cancer – melanoma ,however researcher...ncreased, so has the number of patients surviving ...may have a beneficial influence on some kinds of c...ients who were diagnosed with melanoma in the late...
Other Medicine News:Health News:SARS (Bird Flu) spreading in the Asian continent 2
...int or DIP joint flexioncontractures of any degree... cushions injured fingers so treatment to straight...ster, more successful therapy results. Use during ...aintain gains in motion. Available in small, mediu...
...iation of the finger joints. Lined in gel padding ...ed splints can be worn at night to lessen stress o...owing injury to the PIP joint or DIP joint of the ...gament injuries. Each FingerSled Splint can be use...
FoamWrap Finger Trappers are ideal for use with custom made splints to help restore finger motion. Finger Trappers' non-slip foam lining replaces fingernail hooks and sutures to place the fingers in
One splint does it all.
Medicine Products: